CERIVASTATINE
Cerivastatin inhibits HMGCoA reductase to lower LDL cholesterol but was withdrawn due to rhabdomyolysis risk. Side effects included muscle toxicity and liver enzyme elevation. Only GMP materials will be supplied, logistics all according to GDP.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
Cerivastatin is a potent HMGCoA reductase inhibitor (statin class), blocking the ratelimiting step in cholesterol biosynthesis. By inhibiting conversion of HMGCoA to mevalonate, it reduces intracellular cholesterol, upregulates LDL receptors, lowers serum LDL, and influences downstream isoprenoidmediated signalling pathways affecting inflammation, endothelial function and cellular apoptosis.
Benefits and Advantages
Used in cholesterolbiosynthesis pathway research, statin SAR modelling, cardiovascularrisk biomarker studies, mitochondrial toxicity modelling, rhabdomyolysismechanism studies, and mevalonatepathway signalling investigations.
Side Effects and Risks
Risks include severe rhabdomyolysis (notably dosedependent), hepatotoxicity, renal failure secondary to myolysis, neuropathy and drugdrug interactions via CYP inhibition. Handle with statinclass bioactivity precautions.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C26H34FNO5 |
|---|---|
| Molecular Weight | 459.5 g/mol |
| CAS Number | 145599-86-6 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | Highly solubility |
| Purity | Purity information is available upon request (COA). |
| Synonym | cerivastatin; 145599-86-6; Lipobay; Cerivastatina; AM91H2KS67 |
| IUPAC/Chemical Name | (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)-3-pyridinyl]-3,5-dihydroxyhept-6-enoic acid |
| InChl Key | SEERZIQQUAZTOL-ANMDKAQQSA-N |
| InChl Code | InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
